Circulating interleukin-38 concentrations in healthy adults

Teufel, Lisa U.; Graaf, Dennis M. de; Netea, Mihai G.; Dinarello, Charles A.; Joosten, Leo A. B.; Arts, Rob J. W.

doi:10.3389/fimmu.2022.964365

Cited by 4 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we recently demonstrated that the blood collection method does not influence the IL-38 concentrations detected by enzyme-linked immunosorbent assay (ELISA). 55 We further observed a positive correlation between Ddimer and IL-38 in men of the validation cohort. Elevated D-dimer is a prognostic marker for severe COVID-19, 56 as well as for thrombotic complications, and is associated with increased proinflammatory cytokine levels such as IL-6.…”

Section: Discussionsupporting

confidence: 56%

“…A potential confounder for the detection of IL‐38 may be due to differences between plasma and serum. However, we recently demonstrated that the blood collection method does not influence the IL‐38 concentrations detected by enzyme‐linked immunosorbent assay (ELISA) 55 …”

Section: Discussionmentioning

confidence: 99%

“…However, we recently demonstrated that the blood collection method does not influence the IL‐38 concentrations detected by enzyme‐linked immunosorbent assay (ELISA). 55 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Exploratory analysis of interleukin‐38 in hospitalized COVID‐19 patients

Graaf

Teufel

Nooijer

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction A major contributor to coronavirus disease 2019 (COVID‐19) progression and severity is a dysregulated innate and adaptive immune response. Interleukin‐38 (IL−38) is an IL‐1 family member with broad anti‐inflammatory properties, but thus far little is known about its role in viral infections. Recent studies have shown inconsistent results, as one study finding an increase in circulating IL‐38 in COVID‐19 patients in comparison to healthy controls, whereas two other studies report no differences in IL‐38 concentrations. Methods Here, we present an exploratory, retrospective cohort study of circulating IL‐38 concentrations in hospitalized COVID‐19 patients admitted to two Dutch hospitals (discovery n = 148 and validation n = 184) and age‐ and sex‐matched healthy subjects. Plasma IL‐38 concentrations were measured by enzyme‐linked immunosorbent assay, disease‐related proteins by proximity extension assay, and clinical data were retrieved from hospital records. Results IL‐38 concentrations were stable during hospitalization and similar to those of healthy control subjects. IL‐38 was not associated with rates of intensive care unit admission or mortality. Only in men in the discovery cohort, IL‐38 concentrations were positively correlated with hospitalization duration. A positive correlation between IL‐38 and the inflammatory biomarker d‐dimer was observed in men of the validation cohort. In women of the validation cohort, IL‐38 concentrations correlated negatively with thrombocyte numbers. Furthermore, plasma IL‐38 concentrations in the validation cohort correlated positively with TNF, TNFRSF9, IL‐10Ra, neurotrophil 3, polymeric immunoglobulin receptor, CHL1, CD244, superoxide dismutase 2, and fatty acid binding protein 2, and negatively with SERPINA12 and cartilage oligomeric matrix protein. Conclusions These data indicate that IL‐38 is not associated with disease outcomes in hospitalized COVID‐19 patients. However, moderate correlations between IL‐38 concentrations and biomarkers of disease were identified in one of two cohorts. While we demonstrate that IL‐38 concentrations are not indicative of COVID‐19 severity, its anti‐inflammatory effects may reduce COVID‐19 severity and should be experimentally investigated.

show abstract

Section: Discussionsupporting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploratory analysis of interleukin‐38 in hospitalized COVID‐19 patients

Graaf

Teufel

Nooijer

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…Analyzing IL-38 and rs6743376 in the context Rheumatoid Arthritis (RA) is crucial for several reasons (Teufel et al, 2022). Firstly, understanding IL-38's role offers potential therapeutic avenues by regulating inflammatory responses in RA.…”

Section: Introductionmentioning

confidence: 99%

Interleukin-38 Level and Polymorphism (Rs 6743376) Associated with Rheumatoid Arthritis

Ibrahim Islemeh,

Mubarak,

Elahi

2023

SJARR

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a multifaceted autoimmune disorder defined by persistent inflammation and joint damage. This study explores the intricate relationship between RA severity and interleukin-38 (IL-38), a cytokine having anti-inflammatory properties. Our research reveals a strong connection between elevated plasma IL-38 levels and the severity of RA, indicating IL-38's crucial role in modulating inflammation. Elevated ESR levels in RA patients highlight active inflammation. Genetic analysis shows specific IL-38 polymorphisms associated with RA susceptibility, emphasizing the disease's genetic basis. These findings position IL-38 as a promising indicator for assessing rheumatoid arthritis RA severity by providing valuable insights into its genetic mechanisms. Understanding IL-38-related pathways could revolutionize RA management strategies.

show abstract

Interleukin-38 and cardiovascular pathology: literature review

Alieva,

Baykova,

Pinchuk

et al. 2023

CardioSomatics

View full text Add to dashboard Cite

Cardiovascular pathology is a leading cause of morbidity and mortality. An important task of modern cardiology is the search and study of new biological markers. Scientists’ interest is actively focused on the study of interleukin-38. Interleukin-38 is an anti-inflammatory cytokine and a member of the interleukin-1 family. This study aimed to analyze literature sources devoted to the study of interleukin-38 as a cardiovascular biological marker. Literature sources, including all relevant publications in PubMed (MEDLINE), RSCI, Google Scholar, and Science Direct, were analyzed. The search depth was 9 years. Interleukin-38 is found in the skin, heart, placenta, fetal liver, spleen, thymus, and activated B cells of the tonsils. Interleukin-38 protein is detected in human plasma, serum, and cell cultures by enzyme-linked immunosorbent assay. Interleukin-38 regulates immune and inflammatory responses by binding to its receptors and activating downstream signals. Its deficiency is associated with increased systemic inflammation in aging, cardiovascular diseases, and metabolic diseases. Currently, not much clinical and experimental data have been accumulated regarding the effect of interleukin-38 on the cardiovascular system; however, further studies are expected to demonstrate the possibility of its use as an additional laboratory tool for diagnosis and assessment of prognosis in patients with cardiac problems. Regulating the concentration and expression of interleukin-38 is a promising strategy for the treatment of cardiovascular diseases.

show abstract

Circulating interleukin-38 concentrations in healthy adults

Cited by 4 publications

References 51 publications

Exploratory analysis of interleukin‐38 in hospitalized COVID‐19 patients

Exploratory analysis of interleukin‐38 in hospitalized COVID‐19 patients

Interleukin-38 Level and Polymorphism (Rs 6743376) Associated with Rheumatoid Arthritis

Interleukin-38 and cardiovascular pathology: literature review

Contact Info

Product

Resources

About